Image Analysis Group (IAG), a leader in clinical trial imaging and the use of AI-driven biomarkers, is expanding its footprint in the United States by opening a new office in Cambridge, Massachusetts. This strategic move positions IAG closer to key biotechnology and pharmaceutical companies in the Boston area, facilitating stronger partnerships and providing tailored support for regional clinical trials. The Cambridge office is anticipated to enhance the company’s ability to collaborate with sponsors and contract research organizations engaged in Phase I–III trials and imaging-intensive development projects.
The expansion aligns with IAG’s focus on therapeutic areas such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic, and metabolic diseases. By establishing a presence in the renowned Boston life-sciences ecosystem, IAG aims to improve its collaboration with biotechnology firms, pharmaceutical organizations, academic institutions, and clinical research centers. The company plans to hire locally, creating job opportunities in clinical imaging operations, data science, regulatory support, and business development over the next year or two.
IAG’s new office is set to deliver comprehensive imaging services that include consultation on clinical trial design, optimization of imaging protocols, centralized image analysis, and regulatory-compliant data delivery. This expansion is part of the company’s mission to provide end-to-end imaging solutions and to ensure a seamless integration of their services within the local biotech and pharmaceutical community.
Globally, IAG supports clinical trials across North America, Europe, and the Asia-Pacific region. The company’s operations are structured to deliver standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials, working closely with pharmaceutical, biotechnology, and medtech companies, as well as CROs on multi-center studies.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). The company specializes in imaging-based clinical trial endpoints across various medical fields, including oncology, inflammatory diseases, musculoskeletal, cardiometabolic, and rare disease indications. IAG’s innovative DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.